RxDoctor Payments Data

Minati Swofford

Dermatology · Anderson, INNPI 1346237476

Payments from drug & device makers

$8,796in general payments, 2019–2025

Across 456 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$1K
  • Johnson & Johnson$1K
  • Amgen$643
  • Lilly USA, LLC$594
  • Regeneron Healthcare Solutions, Inc.$505
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$8,37495%
  • Education$4215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,796 in reported general payments places this provider in the 65th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$349,303
Medicare patients
1,166
Services billed
5,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab131$496,788
Skyrizi PenRisankizumab-Rzaa16$334,856
TremfyaGuselkumab22$298,831
Humira(Cf) PenAdalimumab34$293,224
Taltz AutoinjectorIxekizumab30$214,730
RinvoqUpadacitinib29$184,934
OtezlaApremilast37$149,199
Cosentyx Sensoready (2 Pens)Secukinumab13$99,206
Dupixent SyringeDupilumab17$61,923
AdbryTralokinumab-Ldrm16$61,253
Fluorouracil175$10,245
Clobetasol Propionate213$4,822
Ketoconazole290$4,685
Triamcinolone Acetonide282$3,356
Minocycline Hcl110$2,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,043$298,83122 claims
AbbVieRinvoq$1,373$184,93429 claims
AmgenOtezla$643$149,19937 claims
LEO Pharma Inc.Adbry$127$61,25316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 202 dermatology providers in Indiana.

Other dermatology in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →